Tavulus is developed by Fundacio Privada Mon Clinic Barcelona.

What development phase is Tavulus in?

Tavulus is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Tavulus

Fundacio Privada Mon Clinic Barcelona · FDA-approved active Small molecule Quality 0/100

Tavulus, marketed by Fundacio Privada Mon Clinic Barcelona, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Tavulus
Also known as	LAMA
Sponsor	Fundacio Privada Mon Clinic Barcelona
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

ANTES B+ Clinical Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results